CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BELLUS Health Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BELLUS Health Inc
275 Armand-Frappier Blvd
Phone: (450) 680-4500p:450 680-4500 LAVAL, QC  H7V 4A7  Canada Fax: (450) 680-4501f:450 680-4501

This company was Merged or Acquired on 6/28/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board FrancescoBellini 75 1/1/2002 1/1/2002
President, Chief Executive Officer, Director RobertoBellini 43 1/1/2009 1/1/2009
Chief Financial Officer RamziBenamar 1/1/2021 12/7/2020
9 additional Officers and Directors records available in full report.

Business Names
Business Name
BLU
Innodia Inc.
Neurochem Inc.
Neurochem Inc. (CAN)
Thallion Pharmaceuticals Inc.

General Information
Number of Employees: 74 (As of 12/31/2022)
Outstanding Shares: 126,812,170 (As of 6/16/2023)
Shareholders: 15,167
Stock Exchange: TSE
Fax Number: (450) 680-4501
Email Address: info@bellushealth.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024